Study Summary
This trial is studying proton beam radiation therapy and intensity-modulated radiation therapy to see how well they work in preserving brain function in patients with IDH mutant grade II or III glioma.
- Glioma
- Anaplastic Astrocytoma (AA)
- Oligoastrocytoma
- 1p/19q Co-deletion
- Oligodendroglioma
- IDH1 Gene Mutation
- IDH2 Gene Mutation
- Diffuse Astrocytoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: Up to 10 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Arm I (photon-based IMRT, temozolomide)
1 of 2
Arm II (proton beam radiation therapy, temozolomide)
1 of 2
Active Control
Experimental Treatment
120 Total Participants · 2 Treatment Groups
Primary Treatment: Proton Beam Radiation Therapy · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 30th, 2021
Last Reviewed: November 24th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.